Preserving some sanity by Petsko, Gregory A
A popular definition of insanity - frequently misattributed 
to  Albert  Einstein  or  Benjamin  Franklin,  but  probably 
originating with novelist Rita Mae Brown in 1983 - is that 
insanity is doing the same thing over and over again but 
expecting a different outcome. If that definition is a good 
one, then I think there is a possibility that some of the 
people who run American science might want to start 
getting fitted for a new jacket - the kind where the sleeves 
wrap around the front and are tied together in back.
Before I explain why I think that could happen, it’s 
worthwhile going over some of the history of scientific 
funding in the United States in the past 40 years, to see 
how we got ourselves into the situation we’re in now. In 
1971,  the  US  President,  Richard  Nixon  announced  a 
War  on  Cancer.  In  his  State  of  the  Union  address  in 
January of that year, he proclaimed: “I will also ask for 
an appropriation of an extra $100 million to launch an 
intensive campaign to find a cure for cancer, and I will 
ask later for whatever additional funds can effectively be 
used.  The  time  has  come  in  America  when  the  same 
kind of concentrated effort that split the atom and took 
man to the moon should be turned toward conquering 
this  dread  disease.  Let  us  make  a  total  national 
commitment to achieve this goal.” On December 23 that 
same year, he signed the National Cancer Act into law, 
declaring, “I hope in the years ahead we will look back 
on this action today as the most significant action taken 
during my Administration.”
Well,  in  retrospect,  I  think  we  can  all  agree  that  the 
Watergate cover-up probably turned out to be the most 
significant action of his Administration, but this one was 
right up there. The National Cancer Act (P.L. 92-218), “The 
War on Cancer,” gave the National Cancer Institute, one of 
the  institutes  at  the  National  Institute  of  Health  (NIH), 
unique autonomy at NIH with special budgetary authority. 
Over the last four decades it has grown into, by far, the 
largest of the 27 Institutes and Centers that make up the 
biggest biomedical research funding agency in the world. 
Its annual budget is now just a little under $5 billion (out of 
a  total  NIH  budget  of  about  $32  billion)  and  it  is  still 
charged with coordinating the National Cancer Program - 
in other words, the War on Cancer goes on. Now, certainly 
there  have  been  many  victories  in  that  war:  testicular 
cancer  is  no  longer  a  fatal  disease  thanks  to  Barnett 
Rosenberg’s  discovery  of  cisplatinum  as  an  anticancer 
agent; chronic myelogenous leukemia is now treatable by 
Gleevec and other Bcr-Abl kinase inhibitors thanks to the 
discovery by David Baltimore and others that survival of 
that tumor depends on that kinase and the efforts of Brian 
Drucker and Nick Lydon to exploit that discovery; Her-2 
positive breast cancer is treatable by antibodies directed at 
that  cell  surface  protein  thanks  to  the  work  of  Dennis 
Slamon; other forms of breast cancer can now be attacked 
by  aromatase  inhibitors  thanks  to  the  work  of  Angela 
Hartley  Brodie;  multiple  myeloma  now  has  a  treatment 
thanks to the work of Fred Goldberg, who proposed the 
seemingly  insane  idea  that  inhibiting  the  proteasome 
might be beneficial and not all that toxic; and I could give 
many  more  examples  –  the  list  is  a  long  one  and  the 
victories are impressive indeed. But in most of these cases 
the key work, the initial discovery that led to the treatment, 
was not funded as part of the War on Cancer and was in 
many cases - cisplatinum being the greatest example - not 
even done with curing a disease in mind. And of course, 
most cancers, especially solid tumors, are still very hard to 
treat  and  are  often  fatal.  We’ve  won  many  battles,  but 
Congress and the public will be forgiven for asking: just 
how long is this war going to take?
Then, around 1990, came the Human Genome Project. 
Sold  to  the  Congress  and  public  as  an  undertaking 
comparable in scale and significance to the Manhattan 
Project that produced the first atomic bomb, and directed 
by Francis Collins, now Director of the whole of NIH, the 
Human  Genome  Project  (HGP)  was  a  13-year  project 
coordinated  by  the  US  Department  of  Energy  and  the 
National Institutes of Health. During the early years of 
the  HGP,  the  Wellcome  Trust  (UK)  became  a  major 
partner;  additional  contributions  came  from  Japan, 
France, Germany, China, and others. The project goals 
were  to;  identify  all  the  approximately  20,000-25,000 
genes in human DNA; determine the sequences of the 3 
billion chemical base pairs that make up human DNA; 
store  this  information  in  databases;  improve  tools  for 
data analysis; transfer related technologies to the private 
sector, and to address the ethical, legal, and social issues 
(ELSI) that may arise from the project. Note that nowhere  © 2010 BioMed Central Ltd
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that information into new cures for human diseases, yet 
that  was  the  chief  raison  d’etre  given  to  Congress  to 
justify its multi-billion dollar cost. The Human Genome 
Project was completed in 2003, but the National Human 
Genome Research Institute, which grew out of it, is still a 
major  component  of  NIH.  Its  mission  statement  is: 
“NHGRI’s  mission  has  evolved  over  the  years  to 
encompass  a  broad  range  of  studies  aimed  at 
understanding the structure and function of the human 
genome and its role in health and disease. To that end, 
the institute supports the development of resources and 
technology that will accelerate genome research and its 
application  to  human  health.”  Note  the  emphasis  on 
human health, which is in part because Congress and the 
public are increasingly asking NHGRI officials where all 
the promised cures are. 
Finally, let’s look at the unprecedented doubling of 
the NIH budget, from about $13 billion to about $26 
billion,  which  took  place  from  1998  to  2003.  It  was 
this,  more  than  anything  else,  that  led  to  NIH 
becoming the 500-lb gorilla in the scientific funding 
zoo. Selling that to the Congress and public required 
tactics that would have made Willy Loman proud. The 
primary argument was, as you can probably now guess, 
that doubling the budget would lead to faster cures for 
more diseases.
Well,  here  we  are  almost  ten  years  after  that,  and 
members  of  Congress  and  their  constituents  are  now 
starting to get more than just a little impatient. Where, 
they  ask,  are  all  these  promised  cures?  What  is  being 
done with all that money you asked for to help translate 
scientific discovery into better health?
The right answer, of course, is that the cures will come, 
but  that  they  take  a  long  time  and  often  come  from 
directions  that  are  not  obvious  at  the  moment. 
Cisplatinum  was  discovered  by  a  microbial  biochemist 
who  was  interested  in  seeing  what  would  happen  if 
dividing bacteria were placed in an electric field. Modern 
molecular  biology  and  the  whole  of  the  biotechnology 
industry, from which many of these cures will certainly 
arise, has grown out of the discovery that bacteria make 
specific cuts in DNA as a means of telling self from non-
self. The vast majority of disease treatments in use today 
can be traced back to work that had no disease-related 
objective whatsoever; that wasn’t trying to translate into 
anything;  that  was  motivated  by  nothing  more  than 
individual curiosity.
The right answer is also that it takes, on average, about 
15 years and over $1 billion to develop a drug; that for 
every  successful  pharmaceutical,  more  than  6,000 
completely  new  compounds  have  to  be  invented;  that 
most promising therapies fail, in Phase 2 clinical trials, 
because our animal models for diseases are not very good 
at predicting whether a treatment will work in people; 
that the success rate for small molecule drug and even 
biopharmaceutical development is so low that a batting 
average like that would get you drummed out of baseball 
in Little League.
Yet no one in authority seems comfortable giving those 
answers.  Instead,  to  placate  the  public  and  its  elected 
officials, the NIH is now proposing to create a new center, 
aimed specifically at advancing the translation of basic 
research into the clinic. Proposed just a few months ago 
by  Francis  Collins  (http://feedback.nih.gov/index.php/
faq-ncats/#one),  the  National  Center  for  Advancing 
Translational  Sciences  (NCATS)  has  this  as  its  stated 
scientific rationale: 
Rapid progress in scientific research and the increased 
availability  of  innovative  technologies  have  generated 
unprecedented potential for advancing the translation of 
basic discoveries into therapeutics. At the same time, the 
process of drug discovery remains a challenging and risk-
laden endeavor. These opportunities and challenges have 
prompted  the  National  Institutes  of  Health  to  propose 
formation  of  a  new  Center  focused  on  accelerating  the 
development  and  delivery  of  new,  more  effective 
therapeutics.  This  proposed  Center  is  envisioned  to  be  a 
tremendous  resource  for  the  entire  translational  science 
community. It would develop and offer innovative services 
and expertise in moving promising products through the 
development pipeline, as well as develop novel approaches 
to  therapeutics  development,  stimulate  new  avenues  for 
basic scientific discovery, and complement the strengths of 
existing NIH research activities.
Approval  of  this  Center  is  being  rushed  through. 
Why does it seem so important to get it done before 
the end of fiscal year 2012? I think one reason is the 
fear on the part of those pushing for it, that Barack 
Obama may be a one-term President, and that a right-
wing  Republican  Administration  might  so  slash 
federal spending as to make creation of such a Center, 
which  would  have  an  initial  budget  of  at  least  $500 
million, politically impossible. But here is the rationale 
that is being given officially for the haste:
Every family that has ended up at the end of a medical 
odyssey only to learn that we do not yet have an effective 
treatment or cure knows why we are in a hurry. While we 
have  learned  an  enormous  amount  about  disease  and 
health from our research investments, many diseases and 
conditions lack treatments. Dr. Collins, the NIH Director, 
asked a key advisory committee to look at how NIH could 
realign  our  resources  to  speed  development  of  new 
interventions  and  they  concluded  that  the  scientific 
opportunities are here now. NIH feels compelled to move 
quickly to get this proposed new Center running so that it 
may accelerate the important translational work that is 
ongoing at NIH.
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think that’s unclear given the information we have so 
far. Again, the official statement is focused on getting 
to faster cures:
The  central  role  of  the  proposed  Center  would  be  to 
establish and provide focused, integrated, and systematic 
approaches  for  building  new  bridges  that  link  basic 
discovery  research  with  therapeutics  development  and 
clinical  care.  Translational  sciences  are  increasingly 
becoming  multi-sector  endeavors  involving  industry, 
government,  academia,  and  other  sectors.  Through  the 
proposed Center, NIH would play a key role in convening 
these cross-sector collaborations to advance therapeutics 
development.  The  proposed  Center  also  could  …  focus 
research  efforts  in  high-need  areas  that  attract  little 
commercial interest, such as rare and neglected diseases, 
and drug rescue and repurposing research. The functions 
and activities of the proposed Center would include:
  *providing  a  visible,  central  locus  for  access  to 
resources, tools, and expertise related to translational medicine;
  *streamlining  and  improving  the  process  of 
therapeutics development;
  *serving as a catalyst, resource, and convener for 
collaborative interactions by supporting novel and innovative 
partnerships  between  multiple  key  stakeholders,  including 
academia,  government,  industry,  venture  capitalists,  and 
non-profit organizations;
  *expanding the pre-competitive space by, among 
other things, enabling and providing incentives for greater 
sharing  of  scientific  information  and  publication  of 
negative results;
   *supporting  and  strengthening  translational 
medicine  and  therapeutics  research,  including  providing 
access  to  services  and  resources  for  high-throughput 
screening,  assay  development,  medicinal  chemistry,  and 
preclinical modeling;
  *training translational research investigators; and
  *enhancing communication among all stakeholders.
An  obvious  question  is  what  sorts  of  therapeutics 
would be the focus of the proposed Center? From the 
available  information,  it  sounds  like  the  answer  is 
everything  but  the  kitchen  sink:  In  addition  to 
strengthening and streamlining the process of developing 
small-molecule compounds into drugs, the Center would 
support research aimed at accelerating the development of 
a full range of products and techniques for the diagnosis, 
treatment,  and  prevention  of  disease,  including 
diagnostics,  biologics,  medical  devices,  and  behavioral 
interventions. Okay, maybe it’s everything ‘including’ the 
kitchen sink.
And this is where my worry comes in. Regardless of 
what the new Center actually does, the way it is being 
sold  is  the  same  as  the  way  the  War  on  Cancer  and 
Human Genome Project and the NIH budget doubling 
were sold: just let us do this, and you’ll see cure after cure 
emerge as if by magic. But the fact is, curing a disease is 
one of the hardest things that human beings have ever 
tried to do, and the most spectacular cures usually arise 
from work that is originally not aimed at trying to cure 
anything. All the targeted programs in the world aren’t 
going to change that. What they do instead is to ramp up 
expectations that cannot possibly be fulfilled. 
And we’ve seen, in the examples I’ve given and others 
I  could  cite,  that  that’s  exactly  what  has  happened 
every time we have overpromised the curing of disease. 
You can see now why I worry that the NCATS might 
be a case of doing the same thing over and over again 
and  expecting  a  different  outcome.  Which  would  be 
crazy, right?
But I don’t think it has to be that way. I’m not opposed 
in  principle  to  the  idea  of  the  NCATS.  In  fact,  I’m 
intrigued by it. I think that, if the new Center is pitched 
properly and does certain things - and, more importantly, 
does not do certain things - it has a chance to make a 
very positive impact, not just on human health, but on 
the way medical research is perceived. Next month, I’ll 
offer my suggestions for what those things might be.
In  the  meantime,  I  think  it’s  vital  that  we  all 
communicate to the powers that be the importance of 
continuing  to  support,  and  extol,  fundamental, 
hypothesis-driven  and  discovery-oriented  research  that 
is motivated largely by curiosity. Because if we don’t, in 
trying to give people what they say they want, there is 
great danger that not only will we make them increasingly 
frustrated because they aren’t getting it, but also that we 
will stifle, through lack of funding, the creative leaps that 
are actually our best chance of finding it.  Henry Ford put 
it best, I think: “If I had asked people what they wanted, 
they would have said faster horses.”
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